MENU
INMB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
INmune Bio (INMB) Ownership - Who owns INmune Bio?
INmune Bio Inc is a clinical-stage biotechnology company... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
55.56M
P/E Ratio
N/A
Total Cash
33.37M
Projected Growth
N/A
Total Debt
451K
Revenue
50K
Risk (Beta)
1.26
Dividend Yield
N/A
Total Cash/Share
1.26
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
INMB
Capitalization
55.6M
P/E Ratio
N/A
Risk (Beta)
1.26
Dividend Yield
N/A
Total Cash
33.4M
Total Cash/Share
1.26
Total Debt
451K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
50K
ROE
N/A
Book Value
28.9M
P/B Ratio
1.92
Cash Flow
N/A
Earnings
-2.49
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
27K
Current Ratio
4.20
Current Revenue Per Employee
3846.15
Dividends Per Share - Security
N/A
EBITDA
-39.72M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-123.16
Shares Held By Institutions
44.2M
Shares Outstanding - Current
26.6M
Total Liabilities
8.82M
Total Volume MTD
N/A
Value
-1
Gain YTD
-55.246
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. INMB showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
a developer of therapies that harness the patient's immune system to treat cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com